Paper 102 - EFFICACY OF NIROGACESTAT IN PATIENTS WITH DESMOID TUMORS AND POOR PROGNOSTIC FACTORS: PATIENT-REPORTED OUTCOMES, PROGRESSION-FREE SURVIVAL, AND OBJECTIVE RESPONSE RATE IN THE PHASE 3 DEFI TRIAL

Author(s)

• 

  Bruno Vincenzi, MD, PhD

  Professor
  Policlinico Universitario Campus Bio-Medico
  Rome, Lazio, Italy

  Slides

Co-Author(s)

• NB

  Nam Quoc Bui, MD

  Division of Oncology, Department of Medicine, Stanford University
  Stanford, California, United States
• 

  Palma Dileo, MD (she/her/hers)

  Consultant Medical Oncologist @
  University College London Hospitals NHS Foundation Trust
  London, England, United Kingdom
• NF

  Noah Federman, MD

  UCLA David Geffen School of Medicine
  Los Angeles, California, United States
• RR

  Richard F. Riedel, MD

  Duke Cancer Institute
  Durham, North Carolina, United States
• 

  Brian A. Van Tine, MD, PhD

  Professor of Medicine
  Washington University in St. Louis
  Saint Louis, Missouri, United States
• SZ

  Shengfan Zhou, MS

  SpringWorks Therapeutics, Inc.
  Stamford, Connecticut, United States
• TB

  Timothy Bell, MHA

  SpringWorks Therapeutics, Inc.
  Stamford, Connecticut, United States
• YC

  Yucheng Chu, MS

  Sumptuous Data Sciences
  Monmouth Junction, New Jersey, United States
• AL

  Allison Lim, PharmD

  SpringWorks Therapeutics, Inc.
  Stamford, Connecticut, United States
• AO

  Ana B. Oton, MD

  SpringWorks Therapeutics, Inc.
  Stamford, Connecticut, United States
• 

  Bernd Kasper, MD, PhD (he/him/his)

  Medical Director Mannheim Cancer Center (MCC)
  University of Heidelberg, Mannheim University Medical Center, Mannheim Cancer Center (MCC)
  Mannheim, Baden-Wurttemberg, Germany